Afuco™ Anti-CA9 ADCC Recombinant Antibody (Girentuximab), ADCC Enhanced (CAT#: AFC-TAB-H43)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Chimeric antibody to Human CA9.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Normal Tissue
RNA Expression

Specifications

  • Host Species
  • Chimeric
  • Derivation
  • Chimeric
  • Type
  • ADCC enhanced antibody
  • Specificity
  • CA9 (carbonic anhydrase IX, CAIX, MN, G250) [Homo sapiens]
  • Species Reactivity
  • Human
  • Clone
  • Girentuximab
  • Applications
  • ELISA, FC, IP, FuncS, IF, Neut
  • Conjugate
  • Unconjugated
  • Trade name
  • Redectane
  • Generic Name
  • Girentuximab
  • Related Disease
  • Kidney tumours

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • CA9; carbonic anhydrase IX; carbonic anhydrase 9; CAIX; carbonic dehydratase; MN; RCC associated protein G250; pMW1; CA-IX; P54/58N; membrane antigen MN; carbonate dehydratase IX; RCC-associated antigen G250;

Related Resources

  • Biosimilar Overview
Please refer to Girentuximab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Girentuximab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Girentuximab"

Anti-CAIX/CA9 Recombinant Antibody (Girentuximab)
Recombinant chimeric antibody expressed in CHO binding to human CAIX. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.

See other products for "CA9"

Chimeric Antibody

CAT Product Name Application Type
TAB-707 Anti-CAIX/CA9 Recombinant Antibody (Girentuximab) WB, FuncS, IF, Neut, ELISA, FC, IP IgG1 - kappa
TAB-H43 Anti-Human CA9 Recombinant Antibody (Iodine (124I) Girentuximab) ELISA, IP, IF, Inhib IgG1 - kappa

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-0427 Hi-Affi™ Rabbit Anti-CA9 Recombinant Antibody (clone DS427AB) IHC-P, WB Rabbit IgG

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-TAB-H43. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare